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23 items, accounting for 72.8% of variance. Internal reliability for the 3 domains was 
high (Cronbach’s α .84-.96), as was test-retest reliability (intra-class correlation .81-
.96). Concurrent validity was demonstrated through highly significant relationships 
with relevant domains of the SF-36 and the EQ-5D-5L. ConClusions: Preliminary 
results suggest that the Ox-PAQ is a short, valid and reliable measure of participation 
and activity. The measure will now be validated in a range of further conditions and 
additional properties, such as sensitivity to change and predictive validity, will also 
be assessed in the next phase of the instrument’s development.
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PatIent-RePoRted outcomes In studIes PublIsHed In 2014: WHIcH 
dIsease aReas Have been tHe maIn Focus oF clInIcal ReseaRcH?
Martin A
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objeCtives: To determine the disease focus of all papers indexed in the 
PubMed database that included patient-reported outcomes and were published 
in 2014. Methods: An evidence surveillance process was established based on 
a systematic search of PubMed, using key words relevant to the assessment of 
quality of life and patient-reported outcomes and limited to studies published 
in English, in humans, with abstracts, and either clinical trials, observational or 
validation studies or systematic reviews. The surveillance incorporated all studies 
published from 2010 and was updated weekly. Abstracts identified by the search 
that included patient-reported outcomes were indexed according to disease area, 
using the chapter categorisation from ICD-10 as a framework. Articles were included 
if they reported results or a study protocol from a primary research study or were a 
systematic review. To account for the delay in indexing of publications, we included 
all studies with a publication date of 2014 that were indexed in PubMed up to 18 
May 2015. Results: The search identified 1,980 articles published in 2014, 1713 of 
which met the inclusion criteria. Of these, 19% were conducted in patients with 
cancer, 12% in musculoskeletal disorders, 10% in respiratory disorders, 9% in uro-
genital disorders, 9% in mental health disorders, 8% in cardiovascular diseases, 7% 
in gastrointestinal disorders and 5% in neurological disorders. All other disease 
areas were relatively underrepresented, accounting for 4% or fewer of the relevant 
publications. ConClusions: The preponderance of patient-reported outcome 
studies in patients with cancer reflects the focus of pharmacological research on 
this topic. Disease areas such as endocrinology and diabetes (4% of abstracts), infec-
tious diseases (2%), acute trauma (1%) and pregnancy (< 1%) have been relatively 
under-researched for their impact on quality of life, despite their substantial impact 
on morbidity and mortality internationally.
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objeCtives: A comprehensive disease model of PCOS demonstrated that polycystic 
ovary syndrome (PCOS) presents with a broad range of symptoms and has significant 
impacts on patients’ lives. There are no patient-reported outcome (PRO) instruments 
that are well-defined, comprehensive in coverage and reliable for capturing symptoms 
and impacts in women who experience PCOS. The PCOS-PRO was therefore developed 
following the principles outlined in the 2009 FDA PRO Guidance. Methods: The 
following steps were undertaken: (1) a targeted review of the literature, interviews 
with clinical experts, and concept elicitation interviews with PCOS patients were 
conducted to inform a comprehensive disease model of the signs/symptoms and 
impacts most important to women with PCOS; (2) a conceptual framework for the 
PCOS-PRO was designed to reflect the concepts to be measured and their antici-
pated relationships; (3) items were drafted, using patient language derived from 
the interviews; (4) cognitive interviews were conducted with patients to evaluate 
patient comprehension; (5) the conceptual framework was revised and the PCOS-
PRO finalized. Results: The final PCOS-PRO has 39 items measuring menstruation 
symptoms, the daily symptoms of PCOS (pain, cramping, bloating, hirsutism, acne, 
darkened skin, alopecia), and the daily impacts of PCOS (activities of daily living, rest, 
physical limitations, exercise, emotional health, engagement in coping behaviours). 
Most items are evaluated on 11-point numeric rating scales (NRS) anchored with “no 
[symptom/impact]” and “[symptom/impact] as bad as I can imagine”, or “not difficult” 
and “extremely difficult”. The PCOS-PRO has been developed on an e-diary with a 24 
hour recall period for daily use. ConClusions: Establishing content validity involves 
ensuring that instrument items assess concepts that are relevant for the patient 
population, cover all important aspects of the targeted concepts, and are understood 
by patients. The results of this research support the content validity of the PCOS-PRO. 
Other measurement properties are pending evaluation.
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objeCtives: This research aims to provide clarity regarding the location of the 
abdomen from the patient perspective, and the implications that this has for estab-
lishing content valid PRO measures of symptoms experienced in the anatomical 
region. Methods: The dataset included 419 adult participants with either chronic 
obstructive pulmonary disease, depression, osteoarthritis, or type II diabetes. 
Participants were asked to circle the abdomen on a diagram of a body. A grid of 13 
regions, nine of which were used to define the abdomen, was used to analyze which 
region(s) was identified as the abdomen. Results: The average age of the partici-
pants was 55.3 years and they were predominantly female (52.0%) and black (48.0%). 
Only 20.0% achieved a college or advanced degree. 411 participants (98.1%) circled at 
least one part of the abdomen; only 8 participants (1.9%) circled something exclusively 
was more common for premature delivery (p < 0.001). ConClusions: Based on the 
results it can be said that in the study population the education of pregnant women 
was influence to their health-conscious. Among pregnant women who smoked 
less hemoglobin and red blood cell values were experienced which have indirect 
harmful effects to fetus. Anxiety was observed at primiparae, and they were more 
common in premature birth.
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objeCtives: Measurement of preferences gives a quantitative understanding of 
the value that a person places on a medication or a health intervention. The aim 
was to review the evidence regarding patients’ and health professionals’ prefer-
ences towards IV and SC drug administration Methods: A literature review was 
conducted through PUBMED, Google Scholar and ISPOR DATABASE. A hand search 
was also performed in retrieved papers that were included in the final analysis 
to identify additional relevant papers. Search terms used were ‘preference’ AND 
‘IV vs. SC’ OR ‘IV versus SC’ OR ‘intravenous vs. subcutaneous’ OR ‘intravenous 
versus subcutaneous’. Studies should be written in English, published after 2000 
and participants should be adults. Reviews, studies comparing IV and/or SC over 
other routes of drug administration and not evaluating preferences, were excluded 
from the study. Results: 424 papers were retrieved and 8 were identified through 
hand search. Finally, 20 studies met the inclusion criteria. The majority focused on 
patients’ preferences and only 5 studies measured health professionals’ preferences. 
Very few studies used stated-preferences techniques. In 4/5 studies health profes-
sionals stated that they prefer SC administration. No study gave the reasons for 
this preference. In general, patients preferred SC over IV administration. The main 
reasons for that were time, convenience and location. Patients’ age seemed to be 
also important in shaping preferences. ConClusions: In the majority of studies 
patients and physicians prefer SC vs. IV as the route of administration. Patients’ 
education in SC drug administration will increase their confidence regarding self-
injections and the use of SC drug administration. The role of physicians and nurses 
is crucial towards this target. There is a need to identify the specific attributes that 
define health professionals’ preferences regarding the route of administration and 
to develop validated tools to elicit preferences that do not require high degree of 
expertise.
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objeCtives: The therapeutic reference pricing system in Slovenia was imple-
mented for proton pump inhibitors in 2013 and for angiotensin-converting 
enzyme inhibitors and lipid-lowering medicines in 2014. The study aimed to assess 
patients’ knowledge and attitude towards the therapeutic reference pricing sys-
tem. Methods: A representative sample of 676 patients that had been prescribed 
at least one medicine from the three therapeutic classes was surveyed. The survey 
was carried out from 15th May to 15thJune 2014 in 40 community pharmacies with 
the help of the pharmacists, who filled in the first part of the questionnaire in the 
presence of the patients. The second part of the questionnaire was filled in by 475 
patients at home and returned by prepaid mail. Results: Statements describing 
the patient’ rights and duties within the therapeutic reference pricing (TRP) sys-
tem were only known by approx. 50% of the patients or fewer in most of the cases 
presented to them. Of particular concern are elderly, patients with worse health 
condition, and low-income patients that expressed poorer knowledge about the TRP 
system. The patients had an inhomogeneous view of the necessity and benefits of 
the TRP system, including its potential for cost containment. Most of them regarded 
the TRP system as an unnecessary burden, which could even reduce confidence in 
the Slovenian health care system. Among the 50.4 % that were required to co-pay 
due to the TRP system, 46.7% actually co-paid for their medicine, while 3.7% of 
the patients rejected co-payment. On average, the co-payment was 6.92 EUR per 3 
months of therapy, while the average willingness to pay expressed in the study was 
10.4 EUR for three months of treatment. ConClusions: The results of the present 
study indicate that the implementation of the TRP system and potential upgrades 
in the future represent a significant challenge for patients.
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objeCtives: There is growing interest in the management of long term condi-
tions and keeping people active and participating in the community. Testing the 
effectiveness of interventions which aim to impact upon activities and participa-
tion, however, can be challenging without the availability of a well-developed, valid 
and reliable instrument. The objective of this study was to develop and validate a 
fully FDA compliant patient reported outcome measure, the Oxford Participation 
and Activities Questionnaire (Ox-PAQ), theoretically grounded in the World Health 
Organisation International Classification of Functioning, Disability and Health 
(ICF). Methods: Questionnaire items generated from patient interviews and based 
on the nine chapters of the ICF were administered by postal survey to 386 people 
with three neurological conditions; Parkinson’s disease, amyotrophic lateral sclero-
sis, and multiple sclerosis. Participants also completed the MOS 36-Item Short Form 
Survey (SF-36) and EQ-5D 5L. Results: 334 participants completed the survey, a 
response rate of 86.5%. Factor analytic techniques identified 3 domains, consisting of 
